A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults (RSV-OA=ADJ-020)

NCT05966090 PHASE3 COMPLETED Results posted

To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged \>=50 years of age.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE3
Status	COMPLETED
Enrolment	530
Start date	Fri Jul 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Respiratory Syncytial Viruses
• Respiratory Syncytial Virus Infections

Interventions

• RSVPreF3 OA investigational vaccine
• HZ/su vaccine

Countries

Canada, United States